Baxter International, Inc. (BAX)
25.83
+0.26
(+1.02%)
USD |
NYSE |
Sep 04, 16:00
25.80
-0.03
(-0.12%)
After-Hours: 20:00
Baxter International Research and Development Expense (Quarterly) : 125.00M for June 30, 2026
Research and Development Expense (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Research and Development Expense (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 125.00M |
| March 31, 2026 | 124.00M |
| December 31, 2025 | 116.00M |
| September 30, 2025 | 115.00M |
| June 30, 2025 | 134.00M |
| March 31, 2025 | 138.00M |
| December 31, 2024 | 131.00M |
| September 30, 2024 | 129.00M |
| June 30, 2024 | 130.00M |
| March 31, 2024 | 120.00M |
| December 31, 2023 | 127.00M |
| September 30, 2023 | 129.00M |
| June 30, 2023 | 165.00M |
| March 31, 2023 | 157.00M |
| December 31, 2022 | 156.00M |
| September 30, 2022 | 147.00M |
| June 30, 2022 | 148.00M |
| March 31, 2022 | 149.00M |
| December 31, 2021 | 133.00M |
| September 30, 2021 | 129.00M |
| June 30, 2021 | 139.00M |
| March 31, 2021 | 128.00M |
| December 31, 2020 | 132.00M |
| September 30, 2020 | 122.00M |
| June 30, 2020 | 118.00M |
| Date | Value |
|---|---|
| March 31, 2020 | 123.00M |
| December 31, 2019 | 153.00M |
| September 30, 2019 | 134.00M |
| June 30, 2019 | 141.00M |
| March 31, 2019 | 114.00M |
| December 31, 2018 | 165.00M |
| September 30, 2018 | 156.00M |
| June 30, 2018 | 164.00M |
| March 31, 2018 | 137.00M |
| December 31, 2017 | 181.00M |
| September 30, 2017 | 149.00M |
| June 30, 2017 | 154.00M |
| March 31, 2017 | 130.00M |
| December 31, 2016 | 152.00M |
| September 30, 2016 | 102.00M |
| June 30, 2016 | 155.00M |
| March 31, 2016 | 137.00M |
| December 31, 2015 | 158.00M |
| September 30, 2015 | 140.00M |
| June 30, 2015 | 147.00M |
| March 31, 2015 | 143.00M |
| December 31, 2014 | 154.00M |
| September 30, 2014 | 148.00M |
| June 30, 2014 | 324.00M |
| March 31, 2014 | 303.00M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Research and Development Expense (Quarterly) Benchmarks
| Becton, Dickinson & Co. | 258.00M |
| DexCom, Inc. | 153.00M |
| Boston Scientific Corp. | 554.00M |
| West Pharmaceutical Services, Inc. | 19.70M |
| Abbott Laboratories | 892.00M |